INTRODUCTION
The explosion of new human genetic data and an increasing awareness that genetic variation influences drug responsiveness has signaled a new era of pharmacogenetic research. Rich opportunities now exist to dissect the variable pharmacokinetic and pharmacodynamic effects of new and marketed drugs as well as the moleculargenetic basis for disease heterogeneity. Pharmacogenetic investigations should provide important advances in the design, development and delivery of safe and efficacious pharmaceuticals, including opportunities to provide customized drugs for specific patient populations as defined by their unique genotypes. As such, pharmacogenetics represents an important new approach to address directly unmet medical needs of high interest to consumers, health care providers and the pharmaceutical industry. 1 The guidelines and policies of diverse regional or international ethical, regulatory, medical and scientific bodies emphasize the importance of enhancing health care through geneticsbased research. [2] [3] [4] [5] [6] [7] [8] Informed consent (IC) is the means by which potential research subjects make a judgment about the contribution that their involvement in the research can make, relative to the risks or benefits to them as individuals. Pharmacogenetic research in drug development involves special considerations and disclosures in the informed consent process. These disclosures are of practical importance in the context of available options and strategies for incorporating genetic objectives into clinical studies and are of ethical importance in terms of the implications of genetic data to be derived from such studies, including the potential risks for genetic discrimination. However, early experience in the design and implementation of such studies by pharmaceutical sponsors indicates a need for consistent practices in the IC process. In the context of multi-national drug trials and registration efforts, IC policies may be inconsistent among individual institutional review boards (IRB) or independent ethics committees (IEC), and in some cases IRB/IEC requirements may be contradictory among different countries. Several approaches to protecting human subjects in clinical genetic research through IC have been proposed. These have merit in particular contexts, but none of these address all issues in all circumstances. [9] [10] [11] [12] [13] The Pharmacogenetics Working Group (PWG) is a voluntary association of pharmaceutical companies involved in clinical drug trials and genotyping whose goal is to advance the understanding and development of pharmacogenetics by addressing non-competitive ethical, regulatory, and legal issues. This group previously defined harmonizing terminology for sample collection in clinical genetic studies. 1 This communication considers the key elements of the IC process communication are to assist researchers, IRBs/IECs and regulatory agencies in better understanding issues specific to pharmaceutical company-sponsored pharmacogenetic research so that they can best assure protection of subjects, while at the same time facilitating timely review, approval and implementation of pharmacogenetic trials.
INFORMED CONSENT PROCESS FOR PHARMACOGENETIC INVESTIGATIONS
Informed consent can be defined as both the document used to obtain consent as well as the process utilized to communicate the intended disclosures and to ensure accountabilities for the consequences of obtaining consent. Defining the best approach to obtain consent for pharmacogenetic research is challenging. Because genetic terminology and concepts may be intrinsically difficult to understand, study subjects should be encouraged to ask questions to confirm their understanding of the purpose for participating and what is to be learned from the studies. Signature of the person conducting the IC discussion facilitates accountability for this understandable communication and dialogue. When appropriate to enable clear communication, consent materials should be given to subjects prior to the research visit so there is sufficient time for review. In order to facilitate understanding of a pharmacogenetic study, some sponsors have created educational pamphlets and videos as an adjunct to the consent form to provide additional information to assist the subject in making decisions about participation. Also, special attention should be paid to the document itself, to assure that the language is understandable, and at an appropriate reading level and that the risks, benefits and purpose of the study are clearly explained. It is noteworthy that some background information a subject may have received prior to being asked to participate in a pharmacogenetic trial is likely to have come from media or a historical perspective suggesting (to the subject) that a pharmacogenetic trial involves cloning, reproductive choices or risks for serious monogenic disorders. To avoid these possible misconceptions, the IC consent process should explain not only what pharmacogenetics is, but also what it is not.
KEY ELEMENTS FOR DISCLOSURE AND CONSENT IN PHARMACO-GENETIC STUDIES Purpose(s) and Intent of Pharmacogenetic Studies
As is true for all clinical studies, the researcher must describe, in terms understandable to the study subject, the overall objectives of the study and the subject's role in it. For pharmacogenetic studies, the subject should be provided with some background information about the biologic function of genes (for example, that genes affect physical features and health status) and how such studies may help scientists and clinicians learn more about health, disease, and drug treatments.
The specific purpose of the study should be clearly described including both short-term objectives and potential long-term applications. A description of the disease(s) or clinical conditions of investigative interest during the current trial, as well as those disorders of potential interest for study in the future should be described. Depending on the study design, specific language or broad descriptions may be appropriate. Readily understandable study endpoints should be conveyed, such as 'to identify genetic reasons why certain individuals respond differently to drugs' or 'to identify variations of genes which may cause or modify a disease'.
Within certain countries or for specific IRBs/IECs, explicit identification of the genes (or genetic pathways) to be studied may be required for approval. Such IC requirements have the important disadvantage of limiting the use of DNA or other genetic materials for pharmacogenetic evaluations in a way that will not allow researchers or research sponsors to maximize the value of donated samples in light of future knowledge or hypotheses. Moreover, such requirements cannot be satisfied for studies designed to discover unknown genetic determinants of drug response, ie, where no a priori assumption is being made. Since these objectives represent meritorious goals with potentially positive health implications, it may be desirable to limit the imposition of such restrictions.
The IC document should identify all intended uses of the pharmacogenetic information and clinical information to be derived from the study. If the research is sponsored by a commercial entity or has commercial (and intellectual property) implications, this should be clearly described in the IC document because some individuals may choose not to participate in such studies. Plans for archiving the subject's DNA and/or creating immortalized cell lines (which could provide an inexhaustible source of DNA for future studies) should be clearly revealed, and any plans for distribution of the subject's genetic materials to secondary users should be presented, even if such parties are not yet defined. This is of special importance in the context of regulations restricting blood/DNA shipment from certain countries/ regions. Some, but not all, existing guidelines or policy statements imply or state that the study subject has a right to decide (prospectively) the future uses of his/her sample. 9,10 Such guidelines imply a requirement for recontact or re-consent. This option is not always practical or even possible and is dependent on the category and the relative anonymity of the genetic samples collected for a pharmacogenetic study. 1 
Trial Procedures
The IC process for pharmacogenetic trials should clearly describe the procedures involved in collecting and handling samples, and the options available to the patient once a sample has been acquired and genetic information has been derived. These procedures and options will vary depending on the trial design, the research sponsor's internal standard operating procedures (SOP) and the preferences of the researchers and their institutional policies.
Voluntary participation
Enrolment in pharmacogenetic studies requires voluntary participation through IC as for any clinical research protocol.
14 However, pharmacogenetic trials commonly utilize separate IC documents for a drug research protocol and a related pharmacogenetic sampling protocol. The latter is often prepared as an amendment to the main study protocol to enable study subjects to make an informed choice about participating in the pharmacogenetic study independent of their decision to participate in the drug research protocol. A separate IC document for pharmacogenetic sampling must provide sufficient information for the subject to make an informed decision to donate genetic materials based on the merits and risks of the pharmacogenetic objectives and procedures alone. Importantly, this approach allows for efficient patient enrolment in parent drug trials (with optional pharmacogenetic components), which may be compromised if subjects are uncertain whether to volunteer for the pharmacogenetic studies. In studies where the pharmacogenetic aspects cannot be separated from the parent trial (for example, when genotyping is an inclusion criteria), a single consent form is appropriate.
Pharmacogenetic sample collection, storage and distribution A complete description of sample collection procedures (for example, phlebotomy, volume of blood and buccal swab technique) should be part of the IC process. This should include an indication of which procedures are part of routine clinical care, and which are specifically applicable to the pharmacogenetic research objectives, descriptions of who will be handling the samples, and where and how long the samples will be stored. The subject must be informed, if relevant, that enrolment in pharmacogenetic studies may require a detailed family history of disease or other genetic traits, and that such research will require the collection of materials (for example, blood cells, buccal cells, or other tissues) used as a source for the extraction of DNA or other genetic materials. Information concerning sample storage, sample replication (for example, creation of immortalized cell lines), and/or the distribution to third parties (such as other investigators and commercial entities) for additional collaborative studies should be fully disclosed. Specific plans and timelines for sample destruction or depletion should also be defined, especially in the context of subject protection against informational risks (see the section, 'Confidentiality of Subject Information').
Withdrawal options and timelines
In contrast to standard clinical studies or drug trials, the process of 'withdrawal' of subject participation from pharmacogenetic studies may involve a request by the subject (or others) to destroy genetic materials collected. The possibility of this option is dependent on the category of genetic samples as defined in the study protocol, 1 the type and quantity of genetic material collected or derived, and the time interval during which the genetic materials are maintained by the researcher or research sponsor. The IC process should indicate when sample destruction will not be possible, for example, because of pooling of individual samples in the laboratory, and should also indicate the circumstances under which individual genetic results cannot be retrieved, such as after data pooling or entry into anonymous/ anonymized databases. As for drug trials, pharmacogenetic data collected and/or analyzed up to the time of a request by a study subject to withdraw should be maintained by the sponsor, as it is not consistent with good clinical practices to delete individual data from stored data sets.
The IC process should clearly describe the requisite procedures for withdrawal and the time interval or circumstances after which withdrawal may not be possible. In situations where withdrawal is feasible, the sponsor must ensure that logistical capabilities exist to permit the identification and disposal of a pharmacogenetic sample when requested by the subject. An explanation should be provided of the circumstances allowing or preventing the destruction of a genetic sample. For example, it should be explained to subjects that it is possible to destroy an identified, coded, or deidentified/double-coded sample if requested, but that this option is not possible for anonymized or anonymous clinical samples (see Table 1 ). 1 Withdrawal of consent by destroying identified, coded, or de-identified/double-coded samples may be possible, but may be limited by the length of time a researcher or research sponsor maintains study records or by the requirement to maintain data for regulatory submissions. In turn, this time interval may be determined (required) by regulatory guidelines in registration studies. 15 For studies in which samples will eventually be anonymized (for example, following the completion of a registration study) the IC process should indicate that withdrawal may be possible for only a specified time interval (for example, three months) to allow 
Contact information
Information to enable subject contact with the researcher should be clearly indicated on the IC form. This will enable a study subject to obtain further information about the pharmacogenetic research objectives, ask questions regarding his/her rights and responsibilities as a participant, communicate about possible injury due to study activities, communicate about genetic results when available and if appropriate, and/or withdraw from the study. In all situations, the researcher or a designee, or in some circumstances the IRB/IEC should remain the primary contact(s) for the subject.
Options for communication and sharing of genetic results with subjects Any expectations or plans for contact between the subject and the researcher or research sponsor to discuss genetic results or the implications of these results should be clearly described during the process of IC. These must be considered in the context of the specific circumstances of individual studies and the results of genetic assessments including inadvertent genetic discoveries with health implications. Research by pharmaceutical companies involving pharmacogenetic analysis is fundamentally different from genetic testing utilized by patients in the clinical setting, which is performed by accredited clinical laboratories. Typically, genetic testing involves pre-and post-testing discussions of results and their clinical implications by trained genetic counselors. Many factors may influence decisions to share results of pharmacogenetic studies with study subjects, including the standard operating procedures of the research sponsor, the robustness and clinical usefulness of the pharmacogenetic results, the ability of the researchers/sponsors to provide the appropriate counseling, and regional regulations and policy statements from bioethics bodies.
It is important to describe the intended types of pharmacogenetic results to be derived from a study and to inform the subject about the realistic expectations and health implications, if any, of these results. In many types of pharmacogenetic studies, overall results are derived from analysis of aggregate genetic data (ie, population analysis); interpretations of data may be generally applicable to populations but are not specifically applicable to individual subjects. In selected protocols, such as drug trials in which pharmacogenetic data are used as inclusion criteria, it may be possible or even a requirement to discuss individual results of direct interest and benefit to study subjects. However, results of hypothesis-testing pharmacogenetic studies generally should not be shared by sponsors/researchers when they are preliminary in nature, are of no direct medical relevance to the subject, or cannot be used to guide clinical management. Such clinical guidance would not be possible until identified pharmacogenetic markers of drug response were formally validated in confirmatory studies. Moreover, such exploratory pharmacogenetic studies are generally conducted in research laboratories that are less regulated and not in accredited laboratories as for registered genetic diagnostic tests.
The coding category of a genetic sample selected for a pharmacogenetic study dictates the options for future contact to discuss genetic results. 1 For example, contact is not possible for anonymized samples where the key linking clinical and genetic data has been destroyed or in situations where DNA samples are pooled, thus precluding analysis of individual genotypes. Anonymous sampling also prevents any future contacts concerning individual research results. In these situations, aggregate results from population studies may be shared with study subjects in the context of study summaries, published manuscripts or a website posted by the research sponsor summarizing major conclusions or implications of the study. The subject's physician may be in the best position thoughtfully to communicate these results as part of follow-up healthcare contacts. If this is true for a given study and circumstance, this responsibility of the subject's physician should be indicated in the IC form.
Sharing of unintended genetic results
Comparable issues are present with respect to unintended results in non-genetic studies as with the pharmacogenetic results described above, ie, the quality and veracity of individual research results and need for appropriate clinical context for result sharing vs the need for and benefit of disclosure of information to the subject. It should be noted that publically available commercial testing exists for questions concerning monogenic traits; these can be freely accessed by most subjects in an appropriate clinical context outside of the clinical trial. This therefore is the optimal source of genetic testing for individuals seeking such information. Some regional guidelines/laws in fact protect against such disclosures of genetic results, 16 whereas others encourage/require the sharing of genetic results in situations where such information will (or may) favorably impact the quality of life or allow preventative or therapeutic health care. 2, 17 The circumstances requiring disclosure of unintended genetic results including respect for a subject's 'right not to know' must be carefully considered by weighing possible health benefits to the study subject and/or family members against possible informational risks (see the next subsection) implicit in such disclosures.
Risks and Benefits
In conventional trials of investigational drug candidates, the risks and benefits to study subjects are primarily related to the adverse or therapeutic effects of drug exposure. The perception of additional and unique potential risks and benefits associated with conduct of pharmacogenetic studies deserves consideration at the time of IC. Foremost among the potential risks is that of genetic discrimination based solely on public perceptions and societal sensitivities. At the same time, pharmacogenetic studies may offer important and unique benefits, primarily opportunities to define the molecular-genetic basis of variable drug responses. In turn, such information may lead to the development of safer and more efficacious drug regimens and predictive diagnostic tests for medical care. The IC process must convey the relative risks and benefits within the context of these considerations as well as the scientific design and expectations of a pharmacogenetic study.
Risks
As a point of reference, for clinical research that is subject to federal regulation, the United States Code of Federal Regulations dictates that those risks of any magnitude (ie, greater than the risks of everyday life) require warning about the potential for harm.
14 Physical risks associated with the collection of pharmacogenetic samples (sampling of blood, buccal mucosa, or other tissue samples) are not unlike those for other types of clinical research and include adverse events associated with study procedures. The medical risks associated with pharmacogenetic sample donation are generally considered to be low, since donation most often requires phlebotomy or buccal swabbing. In contrast, an issue generally perceived to be of major relevance for clinical genetic research is the possibility of informational risks associated with intentional or inadvertent disclosure of genetic data to third parties (or to study subjects themselves). These perceived risks may pertain not only to the study subject, but also to the close relatives and, in some cases, to the community or ethnic group to which the subject belongs. The IC process should address these risks or concerns and describe the means by which study subjects are protected against such risks, even if these are minimal.
Current societal concerns of informational risk are based in large part on early experience and knowledge of the pathologic significance of genetic tests predicting monogenic traits. 18 These risks may include psychological injury, psychosocial stigma, adverse impact on family relationships, and the potential for insurance or employment discrimination. Some writers have suggested that there is a need for expanded standards of disclosure in IC for human genetic studies beyond the minimal requirements embodied in the US Federal Code of Regulations for the past 20 years. 10, 19 Among the most influential documents signalling a new standard for disclosure in genetic research over the past decade was the OPRR publication in 1993 of Protecting Human Research Subjects: Institutional Review Board Guidebook. 20 Its widespread distribution to IRBs throughout the United States has raised awareness about genetic discrimination that may negatively impact the approval and conduct of pharmacogenetic research sponsored by pharmaceutical companies.
In contrast to the research and diagnostic testing associated with known serious genetic disorders, pharmacogenetic research is not generally associated with high informational risk, as the information generated is limited to the genetic basis of a response to a drug. While the overall risks may be low, these are not negligible in all cases. For example, a defined genetic marker for drug response may be of clinical significance (with health implications) if also shown to be linked to risk for a disease, especially if effective therapies for the disorder do not currently exist. Moreover, it is conceivable that knowledge about differential likelihood to respond, or to react adversely to treatment could be used by insurers in the assessment of overall underwriting risks. As is true for other (non-genetic) clinical investigations, pharmacogenetic studies may involve laboratory or clinical information of high or low sensitivity depending on the specific study. In individual protocols and IC forms, it is desirable to include specific statements, as the risks/implications vary substantially depending on the actual study objectives.
In some instances, procedures dictated by protocol design may lessen or attempt to eliminate the informational risks. Among these are the pooling of samples or data before analysis, eliminating the link between subject identity and genotype results, as with anonymized samples, or instituting protocol-specific procedures that may protect subject confidentiality. A further strategy may be to avoid recording both patient participation and research data in permanent medical notes, thereby protecting against access by those outside the research team. Where applicable, these safeguards should be outlined in the IC form or explained to the subject.
Benefits
A wide range of potential benefits to the biomedical research community and to future patient populations is possible through pharmacogenetic research. However, most pharmacogenetic trials are exploratory in nature and are designed to generate or test specific hypotheses about possible genotype-phenotype relationships. As such, they are not likely to provide direct benefits to study subjects such as benefits expected from use of a highly predictive and marketed genetic diagnostic tests (potentially developed in the future). This reality should be clearly stated during IC. 18 Nonetheless, subjects volunteering for such studies should be informed that their specific genetic results may eventually be beneficial to the research and medical community, and may lead to the discovery and development of new drugs or better outcomes for existing drugs. Any anticipated clinical benefits conveyed during the IC process should make reference to the actual status of genetic research and knowledge, and should convey a realistic expectation of the time interval after which new pharmacogenetic data may meaningfully alter clinical practice. The full potential to derive pharmacogenetic benefits from specific trials and sample sets may be possible only if IC is given that allows broad pharmacogenetic analyses based on studies employing markers representing the full breadth of the human genome, or based on new knowledge or hypotheses generated in the future. This is not possible when analyses are limited to specified genes (see the section 'Purpose(s) and Intent of Pharmacogenetic Studies'). Proposals for reconsent prior to each analysis are logistically difficult, and in some cases impossible, particularly if consent is to be sought years afterwards when both subjects and physicians are no longer accessible.
A clinically relevant genetic marker defined in exploratory studies, validated in independent studies (for example, using validated CLIA or GLP specifications), and then used in subsequent pharmacogenetic trials may be of direct benefit to subjects. For example, it may be possible to shift the risk-benefit ratio for a given subject by selecting an optimal (safer) dosing regimen based on specific genotypic markers. An approved and marketed genetic diagnostic formally derived from such studies would eventually be of direct benefit to future recipients of drugs when used in conjunction with genetic diagnostic information. The potential benefits of applying a predictive genetic marker will depend on the correctness of the pharmacogenetic hypothesis, the nature and strength of associations defined, the genetic profile of the subject, and the relative unmet medical needs being addressed. Numerous beneficial applications are possible including opportunities to use knowledge of metabolism gene variants to optimize dosing regimens for diverse classes of drugs, thereby enhancing therapeutic efficacy or diminishing adverse events associated with exposure in defined subpopulations.
Confidentiality of Subject Information
Concern for informational risks were drivers of the Standards for Privacy of Individually Identifiable Health Information, 21 the EU Data Protection Directive, 22 and other regional or international policy statements or guidelines for safeguarding the privacy of healthcare data. 17 The provisions of these regulations, policy statements, and guidelines differ, but IRBs/IECs are generally now charged with determining whether researchers and research sponsors have taken adequate steps to safeguard genetic information and with evaluating plans for data security. These methods include various coding mechanisms and other procedures designed to insure that genetic information from pharmacogenetic trials is appropriately protected, disclosed and utilized. 17 Those selected for each study should be described (in understandable language) during the IC process.
To enable IRBs/IECs as well as study subjects to understand the level of confidentiality provided, the nature and scope of pharmacogenetic research to be carried out must be clearly defined. The intended uses of samples for analyses of drug-specific genetic associations and/or disease-specific genetic analysis should be described. IRBs/IECs may favor more selective genetic objectives focused on the collection of data concerning a single or limited number of genes, in contrast to broad objectives such as unspecified analyses of all genes (for example, genome-wide scan approach) which may be associated with generation of more data points and hence greater risks including opportunities for inadvertent genetic discoveries. Defined short-term objectives together with timelines for destruction of genetic materials are often considered to provide more certainty of adequate protection.
However, it seems clear that the most important component of subject's privacy protection is rigorous attention by the researcher and research sponsor to data protection SOPs. These procedures should provide well thought-out plans for the handling of subject's withdrawal of specimen, the use of database firewalls, internal stringent data access control, consent for secondary use of samples in additional genetic studies, plans for archiving or destruction of pharmacogenetic samples, and possible options, if any, for future contact with study subjects to discuss genetic results or participation in future studies. Disclosure of these plans should allow both subjects and IRBs/IECs to adequately assess the overall level of confidentiality provided.
The research sponsor/researcher has a responsibility to limit access to genetic data, equally important as their responsibility to limit access to clinical data. The IC process should define those who will have access to genetic data and the conditions under which data access is possible during and after completion of the study. Supplemental materials describing how the current data security systems limit access to subjects' data may be helpful when provided to IRBs/IECs to assist in their ascertainment of the level of data protection. The subject should understand that no disclosures of genetic information are authorized outside of those stipulated during IC or in the research sponsor/researcher's standard operating procedures. For circumstances in which data access by health or regulatory authorities may be required (for example, during study audits), the possibility of government record audits and the procedures by which confidentiality will be maintained should be described. Audit trails may be employed within the research sponsor/researcher's organization as a further safeguard of healthcare data by identifying those who actually have had access to the database.
Coding mechanisms are widely employed to protect subject confidentiality in the conduct of clinical genetic research. 17 Research sponsors/researchers must be able to demonstrate to IRBs/IECs that they possess sufficient expertise and have procedures in place adequately to protect data. Recently defined categories of genetic sample collection afford various levels of security in pharmacogenetic studies based on a spectrum of coding procedures. 1 Identified samples carry the highest potential for inappropriate disclosure because there are no additional safeguards ensuring data confidentiality beyond those generally applied to the remainder of a subject's medical records. Data generated from coded samples are processed in a manner analogous to that of other medical or laboratory data collected in clinical trials. The widespread use of coded clinical and laboratory data in clinical trial conduct has demonstrated an excellent track record in protecting subject confidentiality.
The risk that genetic data may become part of the study subject's permanent medical record is substantially reduced by the use of de-identified/double-coded samples.
1 De-identification requires rigorous procedures dictating the handling of coded genotypic and clinical information; greater confidentiality is achieved by limiting access to the coding keys of databases to a trusted/secure third party, either within or outside the sponsoring entity, thereby significantly reducing the likelihood of inadvertent or unintended disclosure of data to any party including study subjects and researchers. Even these safeguards can be overcome under certain conditions, such as when directed by a subpoena from a court of law or government authority. In the United States, laws/ policies have been established to protect against such disclosures for certain types of research 16 and to protect against genetic discrimination based on disability status. 23 Use of coded or de-identified/double-coded samples is necessary in those trials in which pharmacogenetic analyses and data represent a pivotal part of the drug's registration and label information. These categories allow for the possibility of regulatory audits, which may request decoding of datasets for analysis of an individual's genetic data. Anonymized or anonymous sample categories offer an alternative approach for genetic data security, but these sample categories cannot be selected for registration trials or for studies requiring recontact with subjects. 1 
COMMERCIALIZATION
Clinical research sponsored by pharmaceutical companies or other private entities and some academic institutions, has commercial as well as scientific objectives. In the IC process associated with pharmacogenetic studies, the prospective subject should be informed that the contribution of his/ her pharmacogenetic sample might result in commercial gains or intellectual property for the sponsoring pharmaceutical company (who should be named) or other designated parties. This may eventually result in the development of a pharmacogenetic diagnostic test, the approval of a new drug, the acquisition of intellectual property based on genetic discoveries, and/or the transfer of genetic materials to third parties. 24 Subjects should be informed if other parties may derive direct economic benefit from the study, and importantly, whether they will or will not share in financial gain as individuals. A disclosure of the researcher's financial interest or affiliation with a research sponsor should be provided, regardless of how clinical samples are obtained or the level of confidentiality that is assigned to them.
An explanation of these issues may be beneficial as part of the IC process. For example, it could be explained that any genetic discoveries or commercial products derived from a study would require the collective contributions of many genetic samples as well as the long-term resource commitments of the sponsor. The subject may disagree with any rationale obviating his/her opportunities for financial gain and choose not to participate in the study, but is nonetheless able to make this decision based upon clear disclosures in the IC process. It can be emphasized to the subject that while individual economic benefits may not be possible, a sharing of benefits with the community may be possible (and is intended) through the development of novel drugs or tests eventually to be derived from new genetic knowledge.
Disclosing commercial objectives in the IC process for pharmacogenetic research is a transparent and honest approach and allows study subjects to make an informed choice as to whether to contribute genetic materials. Although this has sometimes been regarded as exculpatory, 25 this wrongly assumes that subjects have a 'right' to remuneration. This issue is not one of 'rights' but of providing a clear and unequivocal basis for subjects to make a knowing and informed choice. This is consistent with the United Kingdom Medical Research Council guidance document stating that the subject needs to understand that he/she is making a donation of the sample for use in research and be informed as to who will be responsible for the custodianship of the sample. 4 Each sponsor of pharmacogenetic research may need to develop internal standards or policies to address commercial issues after consultation with legal representatives. However, a harmonized approach used by researchers, research sponsors, and IRBs/IECs is desirable to facilitate the approval of this research.
Compensation
The process of informed consent for pharmacogenetic research should distinguish the issues of compensation associated with the reimbursement of expenses incurred by subjects who participate in a study from those issues of financial compensation that would be an inducement for subjects to participate in pharmacogenetic research. In general, guidance at the international and national level permits payment for the reimbursement of reasonable expenses or costs (ie, parking, transportation, childcare, and missed work hours) involved in clinical research including genetic research (MRC Guidelines, HUGO). The remuneration of these expenses should be fair and reasonable. Likewise, it is important to indicate the type and amount (where possible) of reimbursement or to indicate if there will be no reimbursement of expenses.
As for investigational drug trials, it is generally considered unacceptable to provide financial compensation to induce research subjects to participate in pharmacogenetic studies. Guidance policies of many international, regional or national ethical-legal bodies prohibit payment for human genetic samples (reviewed by Knoppers et al co-workers 17, 24 ). Selected policy positions maintain that the human genome is 'common heritage of humanity' and not 'personal property' and that human genetic materials are part of the 'person' (vs 'property'), which may only be shared as a 'gift' for research purposes. 'This principle of non-commercialization traces back to the concept of the inherent dignity of the human person and the human body as sacred and distinct from things that can be bought and sold in the marketplace'. 24 The Ethics Committee of The Human Genome Organization in its Statement on the Principled Conduct of Genetic Research contends, 'inducement through compensation for individual participants, families or populations should be prohibited'. 26 The 1997 version of the UNESCO Declaration mandates that 'the human genome in its natural state shall not give rise to financial gain'. 27 Other ethical-legal policies share the opinion that (individual) financial benefit represents 'an inducement which compromises free consent'. 23, 28, 29 The process of IC for pharmacogenetic research should take into consideration these fundamental issues and policy positions. In the context of multinational drug trials with pharmacogenetic objectives, it is probable that no common approach/language will permit the approval and implementation of all studies in all regions or countries. In defining appropriate IC language for individual studies, research sponsors must work together with IRBs/IECs to ensure study approvals while at the same time complying with regional attitudes or laws. For example, in the United States, financial reimbursement of subjects involved in pharmacogenetic as well as other types of clinical research is an accepted practice. This is typically for 'out of pocket' expenses such as travel and/or to remunerate subjects for their personal time and inconvenience of participation in the research trial; these remunerations typically vary depending on the amount of time and nature of procedures involved. If subject compensation is allowed by IRB/IEC approval, the amount and form of compensation should be recorded in the IC form. If prohibited by regional policies, laws or attitudes, the IC language should clearly indicate that study subjects will not be financially or otherwise compensated for their participation.
CONCLUSIONS
Creating an understandable IC form and an effective process for communication of disclosures for pharmacogenetic research that includes the necessary and often complex information and accurately addresses the potential benefits, risks, and procedures is challenging. Study subjects are generally concerned about how their confidentiality will be maintained and how their samples will be used. Some important or unique considerations for pharmacogenetic trials include: unfamiliar terminology; study purpose that may be difficult for subjects to understand; perceived informational risks that may result in discrimination or psychological distress; potential societal benefits such as a better understanding of the underlying causes of variable drug response and discoveries of safer and more effective drugs; possible extended durations of genetic studies that far exceed the subject's participation (and that genetic research can continue indefinitely); potential commercial benefit that the sponsor may derive; and the issue of compensating study subjects. Only by assuring an appropriate IC process and document can subjects fully understand the implications of a decision to participate in pharmacogenetic research.
The 'points to consider' discussed in this communication are intended to highlight elements of pharmacogenetic research encountered by pharmaceutical companies that are of key relevance to the IC process and a subject's participation. It is important to re-emphasize that no rules are uniformly appropriate for all situations. Researchers and sponsors must independently consider in each case what is appropriate to ensure both valuable research and adequately informed subjects. IRBs/IECs and regulatory authorities should, among other factors, take into account the critical need for innovative healthcare research that extends across national and regional boundaries.
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